|
Essential Oils |
Bella Mira Essential Oil Supplements
Essential Oil Information and Use
|
Gluten Free |
Gluten Free Living and Recipes
|
Important Information |
Save Your Computer Free Protection
|
Great Products |
|
FREE Wellness Tests |
Hormone Balance Test New Improved
.gif)
|
Contact Us |
Our Shopping Cart Is:
FDA requests boxed warnings on “conventional” antipsychotics 6-16-08
The U.S. Food and Drug Administration today announced its decision to have
boxed warnings added on the label of "conventional" antipsychotic drugs to
indicate that increased risk of death has been associated with the off-label use
of these medications to treat behavioral problems in older people with dementia.
Boxed warnings are the strongest ones that the FDA can give under the Food and
Drug Administration Amendments Act of 2007 (FDAAA). In 2005, the agency already
demanded similar labeling changes for "atypical" antipsychotic drugs due to
similar association with elevated death risk.
The warning for both classes of drugs is to say that clinical trials suggest
that antipsychotic drugs of both types are linked with an increased risk of
death when used in elderly patients treated for dementia-related psychosis.
"It is important that health care professionals and consumers have the most
up-to-date drug safety information," said Thomas Laughren, M.D., director of the
FDA's Division of Psychiatry Products in the Center for Drug Evaluation and
Research.
"The prescribing information for all antipsychotic drugs will be updated to
describe the risk of death in elderly patients being treated for symptoms
associated with dementia."
Both classes of drugs are dopamine receptor antagonists that block the action of
naturally occurring dopamine in the brain. Abnormally high dopamine action has
been linked to psychosis and schizophrenia.
The difference is primarily in their side effects. Atypical antipsychotic drugs
have a lower incidence of neurological side effects such as involuntary
movements or "tics".
Neither class is approved for use in the treatment of dementia-related symptoms
including forgetfulness, poor memory, and an inability to recognize familiar
objects, sounds, or people.
The FDA approves the drugs primarily for the treatment of symptoms associated
with schizophrenia. But the agency leaves the door open for doctors to use
antipsychotic medications in treatment of patients with symptoms of dementia, a
practice called "off-label" use that the FDA allows.
Two recent observational epidemiological studies examined the risk of death in
elderly patients with dementia who were treated with conventional antipsychotic
drugs and found that the death rates were comparable between those taking
atypical antipsychotic and those using conventional antipsychotic drugs.
These studies, along with the earlier evidence for atypical antipsychotic drugs,
indicate that both types of drugs should be considered to have an increased risk
of death when used in the elderly treated for dementia-related psychosis,
justifying the labeling of the boxed warnings, the FDA has concluded.
The FDA today issued letters to the manufacturers of both types of antipsychotic
drugs, informing the manufacturers of its decision that they should make changes
to drug labeling to indicate the risk. They were asked to change labeling in a
way that all of the drugs carry uniform warning language. The drug makers have
30 days to respond.
The affected conventional antipsychotic drugs include Compazine (prochlorperazine),
Haldol (haloperidol), Loxitane (loxapine), Mellaril (thioridazine), Moban (molindrone),
Navane (thithixene), Orap (pimozide), Prolixin (fluphenazine), Stelazine (trifluoperazine),
Thorazine (chlorpromazine), and Trilafon (perphenazine).
Atypical antipsychotic drugs that have been required to carry a boxed warning
include Clozaril (clozapine) , FazaClo (clozapine), Geodon (ziprasidone),
Invega (paliperidone), Risperdal (risperidone), Seroquel (quetiapine), Zyprexa (olanzapine),
and Symbyax (olanzapine and fluoxetine).
The FDA asked healthcare providers to consider the following when deciding
whether or not to use any antipsychotic drug in elderly dementia patients.
Elderly patients with dementia-related psychosis treated with conventional or
atypical antipsychotic drugs are at an increased risk of death.
Antipsychotic drugs are not approved for the treatment of dementia-related
psychosis. Furthermore, there is no approved drug for the treatment of
dementia-related psychosis. Healthcare professionals should consider other
management options.
Physicians who prescribe antipsychotics to elderly patients with
dementia-related psychosis should discuss this risk of increased mortality with
their patients, patients’ families, and caregivers.
In the meantime, the FDA advised that "people taking antipsychotic drugs should
not abruptly stop taking them. Caregivers and patients should talk to the
patient's health care professionals about any concerns."
Below is some background about antipsychotics for healthcare professionals,
cited from the FDA website.
Information for Healthcare Professionals
FDA ALERT [6/16/2008]: FDA is notifying healthcare professionals that both
conventional and atypical antipsychotics are associated with an increased risk
of mortality in elderly patients treated for dementia-related psychosis.
In April 2005, FDA notified healthcare professionals that patients with
dementia-related psychosis treated with atypical antipsychotic drugs are at an
increased risk of death. Since issuing that notification, FDA has reviewed
additional information that indicates the risk is also associated with
conventional antipsychotics.
Antipsychotics are not indicated for the treatment of dementia-related
psychosis.
This information reflects FDA’s current analysis of data available to FDA
concerning these drugs. FDA intends to update this sheet when additional
information or analyses become available.
--------------------------------------------------------------------------------
To report any unexpected adverse or serious events associated with the use of
these drugs, please contact the FDA MedWatch program and complete a form on line
at http://www.fda.gov/medwatch/report/hcp.htm or report by fax to
1-800-FDA-0178, by mail using the postage-paid address form provided on line, or
by telephone to 1-800-FDA-1088.
FDA is requiring the manufacturers of conventional antipsychotic drugs to add a
Boxed Warning and Warning to the drugs’ prescribing information about the risk
of mortality in elderly patients treated for dementia-related psychosis similar
to the Boxed Warning and Warning added to the prescribing information of the
atypical antipsychotic drugs in 2005.* See the last page of this document for a
list of conventional and atypical antipsychotic drugs.
Considerations for Healthcare Professionals
Elderly patients with dementia-related psychosis treated with conventional or
atypical antipsychotic drugs are at an increased risk of death.
Antipsychotic drugs are not approved for the treatment of dementia-related
psychosis. Furthermore, there is no approved drug for the treatment of
dementia-related psychosis. Healthcare professionals should consider other
management options.
Physicians who prescribe antipsychotics to elderly patients with
dementia-related psychosis should discuss this risk of increased mortality with
their patients, patients’ families, and caregivers.
Background Information and Data
Previously, in April 2005, FDA informed healthcare professionals and the public
about the increased risk of mortality in elderly patients receiving atypical
antipsychotic drugs to treat dementia-related psychosis (April 2005 Public
Health Advisory and Information for Healthcare Professionals). At that time, the
analyses of 17 placebo-controlled trials that enrolled 5377 elderly patients
with dementia-related behavioral disorders revealed a risk of death in the
drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated
patients. Although the causes of death were varied, most of the deaths appeared
to be either cardiovascular (e.g., heart failure, sudden death) or infectious
(e.g. pneumonia) in nature. Based on this analysis, FDA requested that the
manufacturers of atypical antipsychotic drugs include information about this
risk in a Boxed Warning and the Warnings section of the drugs’ prescribing
information.
Recently, two observational epidemiological studies1,2 were published that
examined the risk of death in patients who were treated with conventional
antipsychotic drugs.
Gill et al.1 performed a retrospective cohort study in Ontario, Canada of 27,259
adults, 66 years of age or older, with a diagnosis of dementia between April
1997 and March 2002. The investigators compared the risk for death with use of
an atypical antipsychotic versus no antipsychotic and the risk for death with
use of a conventional antipsychotic versus an atypical antipsychotic. They found
that atypical antipsychotics were associated with increased mortality as
compared to no antipsychotic use as early as 30 days and persisting until study
end at 180 days. The investigators found that conventional antipsychotic use
showed a marginally higher risk of death compared with atypical antipsychotic
use. The causes of death were not reported in this study.
Schneeweiss et al.2 performed a retrospective cohort study in British Columbia,
Canada of 37,241 adults, 65 years of age or older, who were prescribed
conventional (12,882) or atypical (24,359) antipsychotic medications for any
reason between January 1996 and December 2004. The investigators compared the
180-day all cause mortality with use of a conventional antipsychotic versus an
atypical antipsychotic. They found that the risk of death in the group of
patients treated with conventional antipsychotic medications was comparable to,
or possibly greater than, the risk of death in the group of patients treated
with atypical antipsychotic medications. The causes of death with the highest
relative risk were cancer and cardiac disease.
FDA considers that the methodological limitations in these two studies preclude
any conclusion that conventional antipsychotics have a greater risk of death
with use than atypical antipsychotics. FDA has determined, however, that the
overall weight of evidence, including these studies, indicates that the
conventional antipsychotics share the increased risk of death in elderly
patients with dementia-related psychosis that has been observed for the atypical
antipsychotics. The prescribing information for all antipsychotic drugs will now
include the same information about this risk in a Boxed Warning and the Warnings
section.
References
1. Gill SS et al. Antipsychotic drug use and mortality in older
adults with dementia. Ann Intern Med. 2007;146:775-786
2. Schneeweiss S et al. Risk of death associated with the use of conventional
versus atypical antipsychotic drugs among elderly patients. CMAJ.
2007;176:627-632.